MNPR Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Monopar Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.61 |
| 52 Week High | US$1.73 |
| 52 Week Low | US$0.27 |
| Beta | 1.18 |
| 1 Month Change | -15.97% |
| 3 Month Change | -38.28% |
| 1 Year Change | -38.28% |
| 3 Year Change | -89.64% |
| 5 Year Change | n/a |
| Change since IPO | -97.69% |
Recent News & Updates
Recent updates
Is Monopar Therapeutics (NASDAQ:MNPR) In A Good Position To Deliver On Growth Plans?
Feb 27
Will Monopar Therapeutics (NASDAQ:MNPR) Spend Its Cash Wisely?
Mar 02We Think Monopar Therapeutics (NASDAQ:MNPR) Needs To Drive Business Growth Carefully
Nov 16Monopar stock soars 19% as enrollment finishes in phase 2 part of oral mucositis study of Validive
Oct 05We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate
Jul 30Monopar Therapeutics (NASDAQ:MNPR) Is In A Good Position To Deliver On Growth Plans
Mar 28We're Hopeful That Monopar Therapeutics (NASDAQ:MNPR) Will Use Its Cash Wisely
Jul 15Here's Why We're Not Too Worried About Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Situation
Mar 26Monopar nabs U.S. patent covering camsirubicin
Dec 22Monopar Therapeutics selects targeted immuno-therapeutic candidate for COVID-19
Dec 10Monopar launches validive mid-stage study in chemo-induced oral mucositis
Dec 08Monopar Therapeutics EPS beats by $0.02
Nov 12Shareholder Returns
| MNPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | -0.4% | -0.6% |
| 1Y | -38.3% | 5.5% | 22.2% |
Return vs Industry: MNPR underperformed the US Biotechs industry which returned 5.5% over the past year.
Return vs Market: MNPR underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| MNPR volatility | |
|---|---|
| MNPR Average Weekly Movement | 13.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: MNPR's share price has been volatile over the past 3 months.
Volatility Over Time: MNPR's weekly volatility has decreased from 24% to 14% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 10 | Chandler Robinson | www.monopartx.com |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers.
Monopar Therapeutics Inc. Fundamentals Summary
| MNPR fundamental statistics | |
|---|---|
| Market cap | US$10.67m |
| Earnings (TTM) | -US$7.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.4x
P/E RatioIs MNPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MNPR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.61m |
| Earnings | -US$7.61m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.44 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MNPR perform over the long term?
See historical performance and comparison